Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ACACB | O00763 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethylamine SCHEMBL2917696 | 0.91 | ACACB (0.47) | ALDH1A1ACACBANPEPENPEPFOLH1 | |
| Butylamine SCHEMBL2917924 | 0.87 | RARB (0.46) | ALDH1A1ACACBANPEPENPEPFOLH1 | |
| SCHEMBL8763089 | 0.82 | ESR2 (0.42) | ALDH1A1KMT2ATSHRMEN1 | |
| SCHEMBL13643238 | 0.81 | GSK3B (0.53) | ACACB | |
| SCHEMBL28192730 | 0.80 | NPC1 (0.43) | ACACBKMT2ATP53MEN1MAPT | |
| SCHEMBL2851334 | 0.80 | FOLH1 (0.54) | ANPEPENPEPFOLH1 | |
| SCHEMBL7033615 | 0.79 | PTGS2 (0.67) | ADRB3TSHR | |
| SCHEMBL452233 | 0.79 | PTGS1 (0.60) | ALDH1A1ACACBANPEPENPEPFOLH1 | |
| SCHEMBL27959311 | 0.79 | PTGS1 (0.60) | ALDH1A1ACACBANPEPENPEPFOLH1 | |
| SCHEMBL6479259 | 0.79 | ANPEP (0.49) | ALDH1A1ACACBANPEPENPEPFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6558744-B2 | Enhanced resolution matrix-laser desorption and ionization TOF-MS sample surface | WATERS INVESTMENTS LIMITED | 2003-05-06 | — | — | US | claimed |
| US-20020068133-A1 | Enhanced resolution matrix-laser desorption and ionization Tof-ms sample surface | WATERS TECHNOLOGIES CORPORATION | 2002-06-06 | — | — | US | claimed |
| US-6071610-A | Enhanced resolution matrix-laser desorption and ionization TOF-MS sample surface | WATERS INVESTMENTS LIMITED | 2000-06-06 | — | — | US | claimed |
| US-20200209260-A1 | Early Diagnosis and Prognosis of Pre-Eclampsia | Universite De Paris (FR) | 2020-07-02 | — | — | US | disclosed |
| US-9617525-B2 | Phosphotriesterase enzymes, methods and compositions related thereto | NEW YORK UNIVERSITY (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160083702-A1 | NOVEL PHOSPHOTRIESTERASE ENZYMES, METHODS AND COMPOSITIONS RELATED THERETO | NEW YORK UNIVERSITY | 2016-03-24 | — | — | US | disclosed |
| EP-2785707-A1 | NOVEL 2H-INDAZOLES AS EP2 RECEPTOR ANTAGONISTS | Bayer Intellectual Property GmbH (DE) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013079425-A1 | NOVEL 2H-INDAZOLES AS EP2 RECEPTOR ANTAGONISTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-06 | — | — | WO | disclosed |
| US-20110207917-A1 | SAM-6 VARIANTS, TARGET AND METHODS OF USE | PATRYS LIMITED (AU) | 2011-08-25 | — | — | US | disclosed |
| US-7635685-B2 | Bifunctional antibiotics for targeting rRNA and resistance-causing enzymes and for inhibition of anthrax lethal factor | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2009-12-22 | — | — | US | disclosed |
| EP-1789429-B1 | BIFUNCTIONAL ANTIBIOTICS FOR TARGETING RRNA AND RESISTANCE CAUSING ENZYMES AND FOR INHIBITION OF ANTHRAX LETHAL FACTOR | TECHNION RES & DEV FOUNDATION (IL) | 2009-08-26 | — | — | EP | disclosed |
| US-7259019-B2 | Multiple sampling device and method for investigating biological systems | PAWLISZYN JANUSZ B | 2007-08-21 | — | — | US | disclosed |
| EP-1789429-A2 | BIFUNCTIONAL ANTIBIOTICS FOR TARGETING RRNA AND RESISTANCE CAUSING ENZYMES AND FOR INHIBITION OF ANTHRAX LETHAL FACTOR | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD. (IL) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006027784-A2 | BIFUNCTIONAL ANTIBIOTICS FOR TARGETING RRNA AND RESISTANCE CAUSING ENZYMES AND FOR INHIBITION OF ANTHRAX LETHAL FACTOR | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2006-03-16 | — | — | WO | disclosed |
| US-20050276727-A1 | Multiple sampling device and method for investigating biological systems | PAWLISZYN JANUSZ B | 2005-12-15 | — | — | US | disclosed |
| US-20050148522-A1 | Bifunctional antibiotics for targeting rRNA and resistance-causing enzymes and for inhibition of anthrax lethal factor | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. | 2005-07-07 | — | — | US | disclosed |
| US-20040242854-A1 | Chemical capture reagent | GE HEALTHCARE UK LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1402268-A2 | CHEMICAL CAPTURE REAGENT | Amersham Biosciences UK Limited (GB) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003005026-A2 | CHEMICAL CAPTURE REAGENT | AMERSHAM BIOSCIENCES UK LIMITED (GB) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148522-A1 | Bifunctional antibiotics for targeting rRNA and resistance-causing enzymes and for inhibition of anthrax lethal factor | ANTXR2, RNASEH1, RNASEL | ALDH1A1 3836/4885ACACB 1468/4885ANPEP 191/4885 |
| US-20040242854-A1 | Chemical capture reagent | SPPL2B, PRXL2A, PLG | ALDH1A1 2055/4885ACACB 4317/4885ANPEP 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.